As of June 1, 2021, Lutathera is now available in Saskatchewan.

The reimbursement criteria is for patients with unresectable, well-differentiated midgut* neuroendocrine tumors (NET) in patients who have experienced radiographic disease progression during somatostatin analog therapy (e.g., octreotide, lanreotide)

Lutathera (177Lu-dotatate) may be given for a maximum of 4 doses or until disease progression or unacceptable toxicity.